#BEGIN_DRUGCARD DB01330

# AHFS_Codes:
Not Available

# ATC_Codes:
J01DC05

# Absorption:
Not Available

# Biotransformation:
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.

# Brand_Mixtures:
Not Available

# Brand_Names:
Cefotan
Yamatetan

# CAS_Registry_Number:
69712-56-7

# ChEBI_ID:
3499

# Chemical_Formula:
C17H17N7O8S4

# Chemical_IUPAC_Name:
(6R,7S)-7-{4-[carbamoyl(carboxy)methylidene]-1,3-dithietane-2-amido}-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2007-06-30 11:52:27 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem]

# Dosage_Forms:
Injection, solution	Intramuscular
Injection, solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Acenocoumarol	The cephalosporin, cefotetan, may increase the anticoagulant effect of acenocoumarol.
Amikacin	Increased risk of nephrotoxicity
Anisindione	The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione.
Dicumarol	The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol.
Gentamicin	Increased risk of nephrotoxicity
Kanamycin	Increased risk of nephrotoxicity
Neomycin	Increased risk of nephrotoxicity
Netilmicin	Increased risk of nephrotoxicity
Probenecid	Probenecid may increase the serum level of cefotetan.
Streptomycin	Increased risk of nephrotoxicity
Tobramycin	Increased risk of nephrotoxicity
Warfarin	The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Avoid alcohol as it can cause a disulfiram effect.

# GenBank_ID:
Not Available

# Generic_Name:
Cefotetan

# HET_ID:
Not Available

# Half_Life:
In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged

# InChI_Identifier:
InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1

# InChI_Key:
InChIKey=SRZNHPXWXCNNDU-IXOPCIAXSA-N

# Indication:
For prophylaxis and treatment of bacterial infections.

# KEGG_Compound_ID:
C06886

# KEGG_Drug_ID:
D00260

# LIMS_Drug_ID:
1330

# Mechanism_Of_Action:
The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
575.619

# Molecular_Weight_Mono:
575.002143315

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164784033

# Pharmacology:
Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

# Predicted_LogP_Hydrophobicity:
-0.65

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
5.21e-01 g/l

# Primary_Accession_No:
DB01330

# Protein_Binding:
Cefotetan is 88% plasma protein bound.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/cefotet.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Cefotetanum [inn-latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:05 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cefotetan

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
6573313	Nolan RD, Jude DA: The interactions of [14C]cefotetan with penicillin binding proteins of a wide variety of Gram-positive and gram-negative species. J Antimicrob Chemother. 1983 Jan;11 Suppl:169-77.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
pbp3

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7154

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Penicillin-binding protein 3

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q75Y35

# Drug_Target_1_SwissProt_Name:
Q75Y35_STRPN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB01330
